Skip to main content
NCBI home page
The BMJ logoLink to The BMJ
editorial
. 1991 Dec 14;303(6816):1489–1490. doi: 10.1136/bmj.303.6816.1489

Hormonal manipulation of prostatic cancer.

F H Schröder
PMCID: PMC1671807  PMID: 1723636

Full text

PDF
1489

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Béland G., Elhilali M., Fradet Y., Laroche B., Ramsey E. W., Trachtenberg J., Venner P. M., Tewari H. D. A controlled trial of castration with and without nilutamide in metastatic prostatic carcinoma. Cancer. 1990 Sep 1;66(5 Suppl):1074–1079. doi: 10.1002/cncr.1990.66.s5.1074. [DOI] [PubMed] [Google Scholar]
  2. Crawford E. D., Eisenberger M. A., McLeod D. G., Spaulding J. T., Benson R., Dorr F. A., Blumenstein B. A., Davis M. A., Goodman P. J. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med. 1989 Aug 17;321(7):419–424. doi: 10.1056/NEJM198908173210702. [DOI] [PubMed] [Google Scholar]
  3. Fowler J. E., Jr, Whitmore W. F., Jr The response of metastatic adenocarcinoma of the prostate to exogenous testosterone. J Urol. 1981 Sep;126(3):372–375. doi: 10.1016/s0022-5347(17)54531-0. [DOI] [PubMed] [Google Scholar]
  4. Geller J., Albert J. D., Nachtsheim D. A., Loza D. Comparison of prostatic cancer tissue dihydrotestosterone levels at the time of relapse following orchiectomy or estrogen therapy. J Urol. 1984 Oct;132(4):693–696. doi: 10.1016/s0022-5347(17)49829-6. [DOI] [PubMed] [Google Scholar]
  5. Haapiainen R., Rannikko S., Ruutu M., Ala-Opas M., Hansson E., Juusela H., Permi J., Saarialho M., Viitanen J., Alfthan O. Orchiectomy versus oestrogen in the treatment of advanced prostatic cancer. Br J Urol. 1991 Feb;67(2):184–187. doi: 10.1111/j.1464-410x.1991.tb15106.x. [DOI] [PubMed] [Google Scholar]
  6. Huben R. P., Murphy G. P. A comparison of diethylstilbestrol or orchiectomy with buserelin and with methotrexate plus diethylstilbestrol or orchiectomy in newly diagnosed patients with clinical stage D2 cancer of the prostate. Cancer. 1988 Nov 1;62(9):1881–1887. doi: 10.1002/1097-0142(19881101)62:9<1881::aid-cncr2820620902>3.0.co;2-9. [DOI] [PubMed] [Google Scholar]
  7. Iversen P., Suciu S., Sylvester R., Christensen I., Denis L. Zoladex and flutamide versus orchiectomy in the treatment of advanced prostatic cancer. A combined analysis of two European studies, EORTC 30853 and DAPROCA 86. Cancer. 1990 Sep 1;66(5 Suppl):1067–1073. doi: 10.1002/cncr.1990.66.s5.1067. [DOI] [PubMed] [Google Scholar]
  8. Johansson J. E., Andersson S. O., Holmberg L., Bergström R. Primary orchiectomy versus estrogen therapy in advanced prostatic cancer--a randomized study: results after 7 to 10 years of followup. J Urol. 1991 Mar;145(3):519–523. doi: 10.1016/s0022-5347(17)38385-4. [DOI] [PubMed] [Google Scholar]
  9. Labrie F., Dupont A., Belanger A., Lacoursiere Y., Raynaud J. P., Husson J. M., Gareau J., Fazekas A. T., Sandow J., Monfette G. New approach in the treatment of prostate cancer: complete instead of partial withdrawal of androgens. Prostate. 1983;4(6):579–594. doi: 10.1002/pros.2990040605. [DOI] [PubMed] [Google Scholar]
  10. Labrie F., Veilleux R., Fournier A. Low androgen levels induce the development of androgen-hypersensitive cell clones in Shionogi mouse mammary carcinoma cells in culture. J Natl Cancer Inst. 1988 Sep 21;80(14):1138–1147. doi: 10.1093/jnci/80.14.1138. [DOI] [PubMed] [Google Scholar]
  11. Oesterling J. E., Epstein J. I., Walsh P. C. The inability of adrenal androgens to stimulate the adult human prostate: an autopsy evaluation of men with hypogonadotropic hypogonadism and panhypopituitarism. J Urol. 1986 Nov;136(5):1030–1034. doi: 10.1016/s0022-5347(17)45198-6. [DOI] [PubMed] [Google Scholar]
  12. Reiner W. G., Scott W. W., Eggleston J. C., Walsh P. C. Long-term survival after hormonal therapy for stage D prostatic cancer. J Urol. 1979 Aug;122(2):183–184. [PubMed] [Google Scholar]
  13. Thompson I. M., Zeidman E. J., Rodriguez F. R. Sudden death due to disease flare with luteinizing hormone-releasing hormone agonist therapy for carcinoma of the prostate. J Urol. 1990 Dec;144(6):1479–1480. doi: 10.1016/s0022-5347(17)39774-4. [DOI] [PubMed] [Google Scholar]
  14. Waxman J., Man A., Hendry W. F., Whitfield H. N., Besser G. M., Tiptaft R. C., Paris A. M., Oliver R. T. Importance of early tumour exacerbation in patients treated with long acting analogues of gonadotrophin releasing hormone for advanced prostatic cancer. Br Med J (Clin Res Ed) 1985 Nov 16;291(6506):1387–1388. doi: 10.1136/bmj.291.6506.1387. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. van Weerden W. M., van Steenbrugge G. J., van Kreuningen A., Moerings E. P., de Jong F. H., Schröder F. H. Assessment of the critical level of androgen for growth response of transplantable human prostatic carcinoma (PC-82) in nude mice. J Urol. 1991 Mar;145(3):631–634. doi: 10.1016/s0022-5347(17)38409-4. [DOI] [PubMed] [Google Scholar]

Articles from BMJ : British Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES